

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY  
PATENT APPLICATION  
TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	15814-1US-2
First Inventor	Tony ANTAKLY
Title	COMPOUNDS WITH ANTI-KS AND ANTI-HIV ACTIVITY
Express Mail Label No.	

20278 U.S.P.T.O.  
10/733323

121203

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1.  Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original and a duplicate for fee processing)
2.  Applicant claims small entity status.  
See 37 CFR 1.27.
3.  Specification [Total Pages \_\_\_\_\_]  
(preferred arrangement set forth below)
  - Descriptive title of the invention
  - Cross Reference to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to sequence listing, a table, or a computer program listing appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
4.  Drawing(s) (35 U.S.C. 113) [Total Sheets \_\_\_\_\_]
5. Oath or Declaration [Total Sheets \_\_\_\_\_]
  - a.  Newly executed (original or copy)
  - b.  Copy from a prior application (37 CFR 1.63(d))  
(for continuation/divisional with Box 18 completed)
    - i.  DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) name in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6.  Application Data Sheet. See 37 CFR 1.76

7.  CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
  - a.  Computer Readable Form (CRF)
  - b.  Specification Sequence Listing on:
    - i.  CD-ROM or CD-R (2 copies); or
    - ii.  Paper
  - c.  Statements verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

9.  Assignment Papers (cover sheet & document(s))
10.  37 CFR 3.73(b) Statement  Power of (when there is an assignee) Attorney
11.  English Translation Document (if applicable)
12.  Information Disclosure Statement (IDS)/PTO-1449  Copies of IDS Citations
13.  Preliminary Amendment
14.  Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
15.  Certified Copy of Priority Document(s) (if foreign priority is claimed)
16.  Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
17.  Other: Statement Under Section 201.06(a).....

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 CFR 1.76:

Continuation  Divisional  Continuation-in-part (CIP) 09/494,500  
of prior application No. ....

Prior application information: Examiner Jeffrey J. Stucker Art Unit: 1648  
For CONTINUATION OF DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

## 19. CORRESPONDENCE ADDRESS

Customer Number: 020988 OR  Correspondence address below

Name	Ogilvy Renault		
Address	Suite 1600 1981 McGill College Avenue		
City	Montreal	State	Zip Code
Country	Canada	Telephone	Fax

Name (Print/Type)	Paul S. Sharpe	Registration No. (Attorney/Agent)	39,493
Signature	12/11/2003		

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL

## for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 465)

## Complete if Known

Application Number	Not yet assigned.
Filing Date	
First Named Inventor	Tony ANTAKLY
Examiner Name	
Art Unit	
Attorney Docket No.	15814-1US-2

## METHOD OF PAYMENT (check all that apply)

Check  Credit card  Money Order  Other  None

Deposit Account:

Deposit Account Number  
19-5113

Deposit Account Name  
OGILVY RENAULT

The Director is authorized to: (check all that apply)

Charge fee(s) indicated below  Credit any overpayments

Charge any additional fee(s) or any underpayment of fee(s)

Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

## FEE CALCULATION (continued)

## 3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non-English specification	
1812 2,520	1812 2,520	For filing a request for ex parte reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 420	2252 210	Extension for reply within second month	
1253 950	2253 475	Extension for reply within third month	
1254 1,480	2254 740	Extension for reply within fourth month	
1255 2,010	2255 1,005	Extension for reply within fifth month	
1401 330	2401 165	Notice of Appeal	
1402 330	2402 165	Filing a brief in support of an appeal	
1403 290	2403 145	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,330	2453 665	Petition to revive - unintentional	
1501 1,330	2501 665	Utility issue fee (or reissue)	
1502 480	2502 240	Design issue fee	
1503 640	2503 320	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)	
1806 180	1806 180	Submission of Information Disclosure Stmt	
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	80
1809 770	2809 385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 770	2810 385	For each additional invention to be examined (37 CFR 1.129(b))	
1801 770	2801 385	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	


Other fee (specify) \_\_\_\_\_

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 0)

\*\*or number previously paid, if greater. For Reissues, see above

**SUBTOTAL (2) (\$ 0)**

(Complete if applicable)			
Name (Print/Type)	Paul S. Sharpe	Registration No. (Attorney/Agent)	39,493
Signature		Telephone	(613) 780-8676

**WARNING: Information on this form may become public. Credit card information should not be included in this form. Provide credit card information and authorization on PTO-2038.**

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

# OGILVY RENAULT

Direct Dial: (613) 780-8676  
Direct Fax: (613) 230-6706  
psharpe@ogilvyrenault.com

December 11, 2003

CLASS: 514  
SUBCLASS: 002000  
GROUP ART UNIT: 1648

## Mail Stop PATENT APPLICATION

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
U. S. A.

Sir:

**RE: New United States Patent Application**

*Division of U.S. Patent Application Serial No 09/494,500 filed January 31, 2000*

**Title: COMPOUNDS WITH ANTI-KS AND ANTI-HIV ACTIVITY**

**Inventors: Tony ANTAKLY; and Ram M. SAIRAM**

**Assignee: Altachem Pharma Ltd.**

**Our File: 15814-1US-2 PSS:LB:If**

---

Pursuant to Section 201.06 of the *Manual of Patent Examining Procedure*, transmitted herewith for filing is the patent application of:

**INVENTORS:** Tony ANTAKLY; and  
Ram M. SAIRAM

**TITLE OF THE INVENTION:**

**COMPOUNDS WITH ANTI-KS AND ANTI-HIV ACTIVITY**

**DIVISION OF:** United States Patent Application Serial No.: 09/494,500  
Filed: January 31, 2000

**Status:** Allowed on September 8, 2003.

**Chain of Title:** Recorded as follows:

1. From: Tony ANTAKLY; and Ram M. SAIRAM  
To: Université de Montréal

The document was recorded in the United States Patent and Trademark Office at Reel 010538, Frame 0712.

2. From: Université de Montréal

To: Altachem Pharma Ltd.

The document was recorded in the United States Patent and Trademark Office at Reel 010853, Frame 0350.

It is respectfully requested that both assignments described above be recorded against the present application.

I.D.S.: It is respectfully requested that the Information Disclosure Statement filed on May 24, 2000 in connection with Parent Application Serial No. 09/494,500 be transferred over to the present application.

Sequence Listing: It is further respectfully requested that the Compliance Under 37 CFR §1.821-1.825 and Statement Under 1.821(f) filed on January 10, 2001 in connection with Parent Application Serial No. 09/494,500 be transferred over to the present application.

The following documents are enclosed:

- a) Utility Patent Application Transmittal.
- b) Application Data Sheet.
- c) Fee Transmittal Form PTO/SB/17 and Patent Application Fee Determination Record, covering:


Filing Fee (small entity):	\$385.00
<b>Total Number of Claims:</b>	<b>7</b>
Assignment Recordal Fees (2 @ \$40)	<u>\$80.00</u>
<b>TOTAL:</b>	<b>\$465.00</b>

The Commissioner is hereby authorized to charge the above fees and any additional fees which may be required, or credit any overpayment, to our Deposit Account No. 19-5113.

- d) A complete and true copy of the disclosure, claims, abstract, formal drawings (10 Sheets – FIGs. 1-10B), and Declaration from Parent Application Serial No. 09/494,500, together with Statement Under Section 201.06(a).
- e) Preliminary Amendment.

Please note that the address of the agents for the applicant in this matter should be the Montreal address of Ogilvy Renault, Customer No. 020988. Correspondence may be directed to Paul S. Sharpe at the Montreal address of Ogilvy Renault.

Respectfully submitted,



Paul S. Sharpe  
Reg. No. 39,493  
Agent of Record

Encls.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re Application of:** Tony ANTAKLY et al.  
**Filed:** Concurrently herewith  
**Serial No.:** Not yet assigned  
Division of Serial No. 09/494,500  
**Title:** COMPOUNDS WITH ANTI-KS AND  
ANTI-HIV ACTIVITY  
**Class-Subclass:** 514-002000  
**Group Art Unit:** 1648  
**Agent of Record:** Paul S. Sharpe  
Tel. (613) 780-8676  
*psharpe@ogilvyrenault.com*

---

**Mail Stop PATENT APPLICATION**

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
U. S. A.


Sir:

**STATEMENT UNDER SECTION 201.06(a)**

The undersigned Agent hereby states that the application papers attached hereto are a true and complete copy of Parent Application Serial No. 09/494,500, as filed in the United States Patent and Trademark Office on January 31, 2000.

Date: December 11, 2003

By:

Respectfully submitted,  
  
Paul S. Sharpe  
Registration No. 39,403  
Attorney for Applicant  
File No.: 15814-1US-2  
PSS:LB:lf

OGILVY RENAULT  
1981 McCollege Avenue  
Suite 1600  
Montreal, QC  
Canada H3A 2Y1